Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma

BACKGROUND: Sunitinib is a tyrosine kinase inhibitor with effective therapeutic outcomes in patients with renal-cell carcinoma. The study were to analyze the association of single-nucleotide polymorphisms present in cell-free DNA and pharmacokinetics with sunitinib treatment-emergent adverse events...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Zhang, Yuanyuan, Mai, Haixing, Guo, Gang, Bi, Guofang, Hao, Guangtao, Li, Yuanyuan, Wang, Xiaofang, Cheng, Longmei, Wang, Jing, Dong, Ruihua, Liu, Zeyuan, Chen, Lijun, Qu, Hengyan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2018
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5865657/
https://ncbi.nlm.nih.gov/pubmed/29581831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23881
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia